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Sphingosine-1-phosphate (S1P) is a biologically active sphingolipid metabolite that exerts important effects on numerous cellular events via
cell surface receptors, S1P1–5. S1P influences differentiation, proliferation, and migration during vascular development. However, the effects of
S1P signaling on early cardiac development are not well understood. To address this issue, we examined the expression of S1P regulatory enzymes
and S1P receptors during cardiac development. We observed that enzymes that regulate S1P levels, sphingosine kinase and sphingosine-1-
phosphate phosphatase, are expressed in the developing heart. In addition, RT-PCR revealed that four of the five known S1P receptors (S1P1–4)
are also expressed in the developing heart. Next, effects of altered S1P levels on whole embryo and atrioventricular (AV) canal cultures were
investigated. We demonstrate that inactivation of the S1P producing enzyme, sphingosine kinase, leads to cell death in cardiac tissue which is
rescued by exogenous S1P treatment. Other experiments reveal that increased S1P concentration prevents alterations in cell morphology that are
required for cell migration. This effect results in reduced cell migration and inhibited mesenchymal cell formation in AV canal cushion tissue.
These data indicate that S1P, locally maintained within a specific concentration range, is an important and necessary component of early heart
development.
© 2005 Elsevier Inc. All rights reserved.Keywords: Sphingosine-1-phosphate; S1P; Heart; Endocardial cushion; Cardiac; Atrioventricular canal; Embryo; MouseIntroduction
Spingosine-1-phosphate (S1P) is a biologically active
lysophospholipid that is involved in cellular differentiation,
proliferation, migration, cytoskeletal reorganization, and apo-
ptosis (Maceyka et al., 2002; Pyne and Pyne, 2000). S1P action
has been implicated in the regulation of numerous cardiovas-
cular processes, including angiogenesis, vascular permeability,
arteriogenesis, cardiac function, vascular development, and
vascular tone control (Alewijnse et al., 2004; Allende and Proia,
2002; Levade et al., 2001). S1P influences cellular events as an
extracellular ligand that acts through the endothelial differen-
tiation gene (EDG) family of receptors. S1P can also act as an
intracellular second messenger that mobilizes intracellular
stores of Ca2+ and influences cell growth, independent of cell⁎ Corresponding author. Fax: +1 203 737 5972.
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doi:10.1016/j.ydbio.2005.12.013surface receptors (Meyer zu Heringdorf et al., 2003; Olivera et
al., 2003; Pyne and Pyne, 2000).
Sphingosine kinase (SK) converts sphingosine to S1P in
response to various stimuli (Maceyka et al., 2002; Pyne and
Pyne, 2000). Some of the factors that increase SK activity
include vascular endothelial growth factor (VEGF), PDGF,
TNFα, EGF, carbachol, and protein kinase C (Cuvillier et al.,
1998; Pyne and Pyne, 2000). In addition, transforming growth
factor beta (TGFβ) up-regulates SK1 expression (Yamanaka et
al., 2004). S1P is important for cell survival as indicated by the
fact that N,N-dimethylsphingosine (DMS) inhibits SK activity
and induces cell death in rat neonatal cardiomyocytes (Karliner
et al., 2001; Yatomi et al., 1996). S1P can also protect cells from
environmental stresses, as S1P reduced hypoxia induced cell
death in rat neonatal cardiomyocytes (Karliner et al., 2001).
The degradation and inactivation of S1P signaling involve
cleavage into palmitaldehyde and phosphoethanolamine by
S1P-lyase or dephosphorylation by sphingosine-1-phosphate
phosphatase, SPP1 (Johnson et al., 2003; Pyne and Pyne, 2000).
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2000). Reduction of SPP1 activity with small inhibitory RNA
(siRNA) in MCF7 cells reduces enzyme expression resulting in
increased S1P levels within cells and increased S1P secretion
(Johnson et al., 2003).
S1P signaling primarily flows from outside the cell to inside
the cell through G-protein-coupled receptors on the cell surface.
This family of five receptors are designated S1P1–5, formerly
referred to as Edg1, Edg5, Edg3, Edg6, and Edg8 respectively
(Chun et al., 2002; Fukushima et al., 2001). S1P1–3 are widely
expressed in embryonic and adult tissues, including the heart
(Osborne and Stainier, 2003; Watterson et al., 2003). In the
cardiovascular system, S1P1 is highly expressed in cardiomyo-
cytes and vascular endothelial cells, while S1P2 and S1P3 are
primarily expressed in vascular smooth muscle cells and
cardiomyocytes (Alewijnse et al., 2004). S1P4 is primarily
expressed in lymphoid tissue with some expression in spleen
and lung but has not been previously reported in the heart
(Graler et al., 1998; Watterson et al., 2003). S1P5 expression is
generally restricted to brain and spleen but has also been
detected in cardiomyocytes (Liliom et al., 2001; Watterson et
al., 2003).
S1P receptors expressed in the cardiovascular system signal
through a variety of pathways to both promote and inhibit cell
migration. S1P1 activation triggers Rac signaling, which
stimulates endothelial cell migration (Lee et al., 1999). S1P3
signals through Gi, Gq, and G13 and can activate phospholipase
C (PLC), inhibit adenylate cyclase, and promote endothelial cell
migration (Lee et al., 1999; Takuwa, 2002; Windh et al., 1999).
In contrast, S1P2 activation inhibits cell migration in vascular
smooth muscle cells, neutrophils, and B16 melanoma cells
(Arikawa et al., 2003; Bornfeldt et al., 1995; Kawa et al., 1997).
S1P2 activation inhibits Rac signaling and activates Rho
signaling (Ishii et al., 2002; Takuwa, 2002), which inhibits
cell migration, in part through the induction of stress fibers
(Takuwa, 2002).
Initial evidence showing that S1P signaling influences heart
development arose from identification of the miles apart (mil)
mutation in zebrafish, a gene that encodes an S1P receptor most
closely related to S1P2 in mammals. The miles apart mutation
impairs fusion of the bilateral heart tubes leading to cardia bifida
(Kupperman et al., 2000). Although cell migration of the
precardiac cells is initially normal in the miles apartmutation, it
was demonstrated that S1P receptor expression is required in
extracardiac tissue for migration of the primitive heart tubes to
the midline where they fuse to form the definitive heart tube
(Kupperman et al., 2000).
Although targeted deletion of S1P2 or S1P3 alone in mice
had no adverse effects on embryogenesis, deletion of S1P1
caused embryonic lethality between embryonic day (E) 12.5
and E14.5 (Ishii et al., 2002; Liu et al., 2000b; MacLennan et
al., 2001). Embryonic death results from a failure of the vascular
smooth muscle cells (VSMC) to surround and support the
developing vasculature leading to a massive hemorrhage (Liu et
al., 2000b). Additional experiments revealed that recruitment of
the VSMC requires S1P1 expression in the endothelial cells of
the developing vessels (Allende et al., 2003). Recently, S1P1,S1P2, and S1P3 triple null embryos were generated, and they
displayed a more severe phenotype that resulted in embryos
dying earlier, between E10.5 and E11.5, than the knockout of
S1P1 alone (Kono et al., 2004).
These reports indicate that S1P signaling is involved in
early cardiac morphogenesis and maturation of the vascular
system, but little is known about S1P signaling in cardiac
tissue during early heart development. In particular, not much
is known about the expression of S1P signaling components
in the heart during embryogenesis, and there are no reports on
what effects altered S1P levels have on cardiac development.
This report begins to address these issues by demonstrating
that enzymes and receptors involved in S1P signaling are
expressed in the heart throughout early cardiogenesis. In
addition, we illustrate that altered S1P signaling can disrupt
normal heart development and, more specifically, cardiac
cushion development.
Differentiation of the cardiac chambers is accompanied by
septation of the heart, which involves formation of the cardiac
cushions from E9.5 to 12.5. A key step in cardiac cushion
development is transformation of endothelial cells into
mesenchymal cells. These mesenchymal cells differentiate
into fibroblasts and contribute to the formation of mature
heart valves (Chin et al., 1992; Thompson and Fitzharris, 1979).
In both the atrioventricular (AV) canal and outflow tract regions
of the heart, endothelial cells receive signals from the
overlaying myocardium to transform and invade the underlying
extracellular matrix (Runyan and Markwald, 1983). Many
signaling molecules, including TGFβ and VEGF, are involved
in promoting and inhibiting endothelial to mesenchymal cell
transformation (EMT) in the developing heart (Chang et al.,
2004; Dor et al., 2001; Eisenberg and Markwald, 1995; Potts et
al., 1991). Disruption of normal cardiac cushion development
leads to septation or valve defects, which are among the most
common congenital heart malformations observed in humans
(Hoffman, 1995a,b).
This report demonstrates that elevated S1P levels inhibit cell
migration and block endothelial to mesenchymal cell transfor-
mation in atrioventricular canals without inducing cell death.
We also reveal that inhibition of S1P production, through
treatment with dimethylsphingosine (DMS), leads to cell death
in AV canal cells and loss of cardiomyocyte function. These
data illustrate the need to carefully regulate the level of S1P
during cardiac development, since S1P signaling influences cell
migration, differentiation, and cell survival of embryonic
cardiac cells.
Materials and methods
Chemicals
Sphingosine-1-phosphate (S1P; Sigma) was resuspended in 4% fatty acid-
free bovine serum albumin (FAF-BSA; Sigma) to 5.25 mM by sonicating for
15 min at 4°C followed by incubation at 45°C for 1 h. N,N-dimethyl-
sphingosine (DMS; Sigma, St. Louis, MO) was dissolved in 100% ethanol to a
final concentration of 3.2 mM. SEW2871 (Ryan Scientific, Inc., Isle of Palms,
South Carolina) was resuspended to 10 mM in dimethylsulfoxide (DMSO).
Fumonisin B1 (FB1; Sigma) was dissolved in water to a final concentration of
500 μM.
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Timed matings were used to obtain the appropriate stage embryos, with E0.5
being the day a vaginal plug was observed. For RT-PCR, total RNA was
collected from whole mouse embryos or isolated hearts at E7.5 to E12.5 and
from AV canals dissected from E9.5 hearts with the RNeasy kit (Qiagen,
Valencia, CA). Embryonic and cardiac tissue was homogenized in 600 μl of
lysis buffer by passing it through a 20-gauge needle 10 times, followed by total
RNA isolation according to the animal tissue protocol provided with the RNeasy
kit. Next, 1 μg total RNA was reverse transcribed with SuperScript III
(Invitrogen, Carlsbad, CA) in a 20 μl reaction with Oligo-dT12–18 primers
according to manufacturer's recommendations. All PCR reactions contained 2×
Master Mix (Promega, Madison, WI) with 100 ng of cDNA and 100 ng of each
primer and were performed at an annealing temperature of 55°C for 35 cycles
with the GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA).
All PCR primers were designed against mouse sequences and include
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control
(forward 5′-TCAACGACCCCTTCATTGAC-3′, reverse 5′-ATGCAGGGAT-
GATGTTCTGG-3′). Primers for sphingosine kinase 1, sphingosine kinase 2,
and S1P phosphatase 1 were as reported (Pettus et al., 2003). The primers for the
S1P1–4 receptor genes were as reported (Forrest et al., 2004). S1P5 primers were
designed based on another report (Wang et al., 2002). All of the primer pairs,
except for SK1, were designed to flank an intron to prevent detection of genomic
DNA. No DNA contamination was detected in any of the RT-PCR reactions, and
the negative control PCR reactions (no template) for all of the primer pairs were
negative (data not shown).
Whole embryo cultures (WEC)
C57BL/6 mice (Charles River Laboratories, Wilmington, MA) were used for
all whole embryo and AV canal culture experiments. Following timed matings,
E7.5 or E9.5 embryos were dissected from the uterine muscle in cold 1×
Dulbecco's phosphate-buffered saline (D-PBS, Invitrogen). Embryos were
transferred to fresh D-PBS to further dissect out the embryos and remove
Reicherts's membrane while leaving the yolk sac intact. Embryos were
transferred to 60-ml bottles (Wheaton, Millville, NJ) containing 5 ml 100% rat
serum and cultured in a roller bottle system at 38°C for 24–48 h, as described
(Sturm and Tam, 1993; Wei et al., 2001; Zhao and Rivkees, 2003). Drugs
(vehicle, 5 μM S1P, or 5 μMDMS) were added to the serum before the addition
of 5–6 embryos per bottle.
Embryonic morphology was assessed following whole embryo cultures with
a Zeiss Stemi 2000-C dissecting microscope. Digital images were captured for
each embryo with an Olympus DP 10 camera.
Heart morphology was assessed by immunocytochemistry following WEC.
Embryos were collected after 48 h of drug treatment and fixed in 4%
paraformaldehyde (PFA, Sigma) overnight at 4°C. Following a wash in D-PBS,
embryos were permeabilized with PBST (PBS with 0.5% Triton X-100) for 2
h followed by blocking with 2% BSA in PBST for 2 h both at room temperature.
Embryos were incubated with a primary antibody to myosin heavy chain
(MF20, Developmental Studies Hybridoma Bank, Iowa City, IA) overnight at
4°C, followed by a secondary antibody (GAM IgG conjugated to Alexa Fluor
488, Molecular Probes, Eugene, OR) incubation for 2 h at room temperature.
Immunostaining was analyzed and documented with an Olympus Fluoview
laser scanning confocal microscope.
E9.5 embryos treated for 24 h with vehicle, 5 μM S1P, or 5 μM DMS in the
whole embryo culture system were used for histological examination of cardiac
structures. Following fixation with 4% PFA, embryos were embedded in
paraffin and sectioned with a Micron HM325 microtome (Walldorf, Germany).
Slides containing 7 μM thick sections were deparaffinized and rehydrated
through a series of ethanol/water washes. Sections were stained with Harris
modified hematoxylin and eosin Y, both from Fisher Scientific (Fair Lawn, NJ)
according to standard histological procedures.
Atrioventricular (AV) canal cultures
AV canal cultures were prepared from E9.5 mouse hearts, as described
(Camenisch et al., 2002). Briefly, embryos were isolated from the uterus in coldD-PBS, and AV canal regions were dissected away from the heart and sliced
open using fine forceps. AV canals were stored in D-PBS on ice until all AV
canals were isolated. They were then placed on collagen gels (1 mg/ml of rat tail
type I collagen, Cohesion, Palo Alto, CA) in 4-well culture dishes (Nalge-Nunc,
Naperville, IL). Three AV canal explants were placed endothelial side down on
each collagen gel and incubated at 37°C in the presence of 5% CO2. After 2 h of
incubation, vehicle, S1P, SEW 2871, FB1, or DMS was added directly to the
explants to give final concentrations of drug in the gel cultures ranging from 0.1
μM to 5.0 μM. Cultures were treated again at 24 h and then allowed to grow
further for a total of 48 h. The explants were assessed for cardiomyocyte
contractions at 24 and 48 h to assess the health of the cultures. Photographs were
taken of each explant at 48 h to assess the extent of outgrowth from the explant
and the amount of EMT.
Live AV canal cultures were imaged with phase contrast methods on an
Olympus IX70 inverted microscope. Digital photographs of the explants were
taken with a color CCD camera (DEI-750-T, Image Processing Solutions, North
Reading, MA). Photos were used to quantitate cellular outgrowth following drug
treatment of cultures. The amount of cellular outgrowth away from the muscle
explant was calculated with the help of the Image-Pro Plus software (Media
Cybernetics, Silver Springs, MD). The extent of outgrowth was outlined
manually for each explant, the measurement was taken twice, and the average
was used to calculate the total area of the explant and surrounding cellular
outgrowth. Next, the muscle explant area was calculated and subtracted from the
total area to give the final area of cellular outgrowth. The outgrowth area for
each drug treatment or vehicle control was determined by averaging several
explants over multiple experiments, with the P value determined by a Student's t
test provided with the Microsoft Excel program. Outgrowth area is presented as
a percent of vehicle control, specific for each drug treatment, and the error bar is
a measure of the standard error of the mean.
Cell viability assays were performed on AV canal cultures grown for 48 h.
The LIVE/DEAD Viability/Cytotoxicity kit (Molecular probes) was used
according to manufacture's recommendations to asses cell viability. Briefly,
cultures were rinsed two times with 1× D-PBS and then incubated with 2 μM
calcein AM and 4 μM ethidium homodimer-1 (EthD-1) in D-PBS for 30 min at
room temperature. Cultures were examined and photographed with an Olympus
Fluoview laser scanning confocal microscope.
The level of apoptosis in AV canal cultures was assessed after drug treatment
with the In Situ Cell Death Detection kit (Roche, Mannheim, Germany)
according to the manufacturer's instructions, as reported (Wendler et al., 2003;
Zhao and Rivkees, 2003). Briefly, AV canal cultures were fixed overnight with
4% PFA at 4°C, followed by permeabilization with 0.3% Triton X-100 for 20
min at room temperature. Cultures were incubated with the TUNEL enzyme for
1 h at 37°C and counterstained with propidium iodide. TUNEL staining was
assessed and documented with an Olympus Fluoview laser scanning confocal
microscope.
The actin cytoskeleton of AV canal cells were visualized with phalloidin
conjugated to Alexa Fluor 488 (Molecular Probes) and counterstained with an
antibody to myosin heavy chain to identify cardiomyocytes. AV canals were
cultured for 48 h then fixed in 4% paraformaldehyde for 2 h at room
temperature. Next, cultures were blocked with 2% goat serum/2% bovine serum
albumin in PBS for 2 h at room temperature. Primary antibody, MF20, was
diluted 1/20 in blocking solution and incubated on the cultures overnight at 4°C.
Next, cultures were incubated with the secondary antibody goat anti-mouse IgG
conjugated to Alexa Fluor 546 (Molecular Probes) at 1/200 dilution and
phalloidin-Alexa 488 at 1/50 dilution in blocking buffer for 3 h at room
temperature. Collagen cultures were mounted on microscope slides with
Fluoromount-G (Electron Microscopy Sciences, Hatfield, PA), and images were
taken with an Olympus Fluoview laser scanning confocal microscope.Results
Enzymes and receptors responsible for S1P signaling are
expressed in developing embryonic and cardiac tissue
Two sphingosine kinase enzymes (SK1 and SK2) and two
sphingosine-1-phosphate phosphatase enzymes (SPP1 and
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(Argraves et al., 2004; Johnson et al., 2003; Liu et al., 2000a;
Mandala et al., 2000). These enzymes are responsible for
regulating the local concentration of S1P (Pyne et al., 2004;
Watterson et al., 2003). Reverse transcriptase PCR was used to
assess the expression of genes encoding these enzymes in whole
mouse embryos and cardiac tissue at early developmental
stages.
SK1, SK2, and SPP1 mRNA expression was detected as
early as E7.5 in whole mouse embryos and throughout early
embryonic development up until E12.5, older embryos were not
examined (Fig. 1A). Expression of SK1, SK2, and SPP1 mRNA
was also observed in isolated cardiac tissue beginning at E8.5
and throughout cardiogenesis up to E12.5 (Fig. 1A). Expression
of the S1P enzymes' mRNAwas detected in AV canals isolated
from E9.5 hearts (Fig. 1A), and their expression was also
observed after E9.5 AV canals were cultured on collagen gels
for 48 h (data not shown).
An important part of S1P action involves signaling through
cell surface receptors (Anliker and Chun, 2004). To determine
which of the known S1P receptors are expressed during cardiac
development, RT-PCR was performed on whole embryo and
isolated heart RNA. We detected S1P1–4 but not S1P5
expression in heart tissue from E8.5 to E12.5 (Fig. 1A).Fig. 1. Genes involved in S1P signaling are expressed in murine embryos and hearts th
RNA isolated from whole embryos (E7.5), whole embryos without hearts (E8.5–E1
reactions were done with an equivalent amount of cDNA following RT reactions wi
DNA contamination (data not shown). (B) Total RNA was isolated from neonatal o
embryo and heart RNA. S1P5 primers produced a single product of the predicted si
glyceraldehyde-3-phosphate dehydrogenase; SK1, sphingosine kinase 1; SK2, sp
sphingosine-1-phosphate receptors 1–5.S1P1–4 receptors were also detected in isolated AV canals from
E9.5 hearts before and after 48 h in culture on collagen gels
(Fig. 1A and data not shown). S1P1–4 but not S1P5 expression
was detected by RT-PCR in embryos without hearts from E7.5
to E12.5 (Fig. 1A). Effectiveness of the S1P5 primers was
confirmed by RT-PCR preformed on RNA isolated from
neonatal oligodendrocytes (Fig. 1B).
Alteration in S1P signaling disrupts embryonic development
After demonstrating that components of S1P regulation and
signaling were present in the heart during early embryonic
development, whole mouse embryo cultures were used to
explore the role of S1P signaling during cardiogenesis. The
advantage of whole embryo cultures is the ability to add
reagents directly to the developing embryos and determine their
effect on embryogenesis independent of maternal factors. We
examined the effects of elevated S1P levels through addition of
exogenous S1P and the effects of decreased S1P production
with DMS treatment.
A range of S1P concentrations (1 μM to 10 μM) were
tested based on reported doses used for treating cells in culture
(Robert et al., 2001; Sanna et al., 2004). It was observed that 5
μM S1P was the lowest dose that gave a consistent phenotype.roughout embryogenesis. (A) Reverse transcriptase-PCR was performed on total
2.5), whole hearts (E8.5–E12.5), and AV canal regions of E9.5 hearts. All PCR
th 1 μg total RNA. Negative controls for all the primers confirmed no genomic
ligodendrocytes and used for RT-PCR under the same conditions described for
ze, thus confirming their effectiveness. L, 1KB DNA ladder (Gibco); GAPDH,
hingosine kinase 2; SPP1, sphingosine-1-phosphate phosphatase 1; S1P1–5,
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whole embryos at E7.5 consistently resulted in smaller
embryos with disrupted morphology, including abnormal
heart formation (Fig. 2). Elevated S1P levels also disrupted
cardiac development when older embryos were cultured.
Treatment of E9.5 embryos with 5 μM S1P for 24 h caused
dilation of the primitive ventricle and reduced cellularity in
AV canal cushions (Fig. 3). S1P-treated embryos had heart
rates consistent with control embryos treated with vehicle
(data not shown).
Next, we examined effects of blocking S1P production. A
range of DMS doses (1 μM to 10 μM) was evaluated with
the whole embryo culture system based on reported
effectiveness of DMS on cultured cells (Karliner et al.,
2001). It was observed that 5 μM DMS gave the most
consistent phenotype in whole embryo cultures without
killing the embryo. DMS-treated E7.5 embryos were much
smaller and had reduced cellularity in cardiac tissue, as seen
by a reduction in myosin heavy chain and propidium iodide
staining compared to vehicle treated embryos (Fig. 2). DMS
treatment of E9.5 embryos also affected cardiac development
including reduced cellular invasion of AV canal cushions
(Fig. 3).
Elevated heart rates were observed for E7.5 DMS-treated
embryos, a sign that the hearts could be undergoing cardiac
failure (data not shown). Altered S1P signaling had no direct
effect on heart rate, based on the addition of either S1P or DMS
to isolated E12.5–13.5 hearts (vehicle, N = 6; 5 μM S1P, N = 6;
5 μM DMS, N = 6). Heart rates were measured at 5, 15, and 60
min after treatment.Fig. 2. Altered S1P signaling disrupts embryogenesis in vitro. Whole embryos were c
or (C, E) 5 μM DMS. MF20, an anti-myosin heavy chain antibody, was used to high
with propidium iodide (red stain) which labels all nuclei. S1P treatment disrupted em
embryonic and cardiac development (C) compared to vehicle control (A). Higher m
myosin heavy chain expression in the heart (E) compared to vehicle control (D). Imag
Scale bar equals 100 μM. H, head; V, ventricle; T, tail.Elevated S1P concentration inhibits cell migration and blocks
endothelial to mesenchymal cell transformation (EMT) in AV
canal cultures
Whole embryo cultures revealed that elevated S1P levels
affected AV canal development by reducing the number of cells
in the cardiac cushions. A similar effect on cushion develop-
ment was reported with elevated levels of VEGF, which like
S1P is a potent angiogenic factor (Dor et al., 2001). In order to
investigate the mechanism of S1P action on cardiac cushion
development, isolated AV canals were cultured on Type I
collagen gels. This system has been used extensively to
examine signaling pathways involved in endothelial to
mesenchymal cell transformation in cardiac cushion tissue. In
this report, AV canal cultures were used to assess the effect of
altered S1P signaling on the health of AV canal tissue which
consists of three cell types, endothelial cells, mesenchymal
cells, and cardiomyocytes. These cultures were also used to
monitor cell migration onto the surface of the gels as well as
formation of mesenchymal cells that invade the collagen matrix.
To assess elevated S1P levels on AV canals, explants were
incubated with a range of S1P doses (from 0.1 to 2.5 μM final
concentration). The health of S1P-treated AV canals was
monitored by several methods. First, we determined whether
explants were beating after 24 and 48 h in culture as an indicator
of explant health, specifically cardiomyocyte health. Vehicle
control and 0.1 μM S1P-treated cultures both had 100% of their
explants beating at 24 and 48 h (Table 1, data not shown). At the
highest concentration of S1P (2.5 μM), 96% of the explants
were still beating after 48 h in culture (Table 1).ultured for 48 h as described and treated with (A, D) vehicle only, (B) 5 μM S1P,
light cardiac tissue (green stain) in these embryos. Embryos were counterstained
bryonic and cardiac morphology (B). Disruption of S1P production also altered
agnification of a DMS-treated embryo shows reduced cellularity and reduced
es are stacked confocal pictures of a Z-series taken through each of the embryos.
Fig. 3. Altered S1P signaling disrupts cardiac cushion development. E9.5 mouse embryos were treated for 24 h in the whole embryo culture system with vehicle control
(A), 5 μM S1P (B), or 5 μM DMS (C). S1P- and DMS-treated embryos had fewer mesenchymal cells within the AV canal cushions (AV). A, primitive atrium; V,
primitive left ventricle. Rostral end of the embryos extends to the top of the pictures. Scale bar equals 100 μM.
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cardiac development without causing cell death. To confirm this
observation, AV canal cultures were stained with the LIVE/
DEAD Viability/Cytotoxicity kit. After culturing AV canals for
48 h with 2.5 μM S1P or vehicle control, live cultures were
treated with the LIVE/DEAD assay and examined with a
scanning laser confocal microscope. This kit stains live cells
with calcein AM, which fluoresces green when excited, and
dead cells with ethidium homodimer-1, which fluoresces red.
This viability assay revealed that S1P treatment of AV canals
did not increase cell death, in either cells on the collagen gel
surface or endothelial cells or cardiomyocytes within the
explanted heart tissue, compared to the vehicle control (Fig.
4). Cell death was examined further with TUNEL analysis. This
also demonstrated that S1P treatment does not significantly
increase apoptosis in AV canal cultures (data not shown).
Next, cell migration and EMTwere examined in S1P-treated
AV canal cultures. The lowest concentration of S1P (0.1 μM)
tested had no effect on either cellular outgrowth or mesenchyme
formation in AV canal cultures (data not shown). Addition of
0.5 μM of S1P to AV canal cultures reduced cell outgrowth
away from the muscle explants by 39%, as compared with
vehicle (Fig. 5). The morphology of the migratory cells on the
surface of the collagen did not appear altered, but there was a
39% reduction in the number of explants with at least 3
mesenchymal cells invaded into the collagen gel after 48
h (Figs. 6). The average number of mesenchymal cells that
invaded into the collagen gel in control explants was 33.75 ± 4
(N = 20). So explants identified as inhibited (fewer then 3
mesenchymal cells) have at least a 95% reduction in the number
of transformed cells invading the collagen gel.
At 1.0 μM of exogenous S1P treatment, cellular outgrowth
away from AV canal explants was inhibited 61%. Not only wereTable 1
Percent of atrioventricular canal explants beating after drug treatment
Treatment After 24 h in culture After 48 h in culture
Vehicle 100% (N = 45) 100% (N = 48)
2.5 μM S1P 100% (N = 25) 96% (N = 25)
2.5 μM DMS 69% (N = 29) 27.6% (N = 29)
2.5 μM DMS + 0.5 μM S1P 92.9% (N = 14) 78.6% (N = 14)cells unable to migrate away from the explants, treatment was
also associated with fewer cells on the surface of the gel. Cells
on the surface of the gel had fewer cellular processes extending
away from their cell bodies, and many were completely round
(Fig. 5). In addition, mesenchymal cell formation was inhibited
by 62% with moderate S1P (1.0 μM) treatment (Fig. 6).
2.5 μM S1P treatment severely inhibited outgrowth from AV
canal explants, with a reduction of greater than 75% compared
to vehicle controls (Fig. 5). S1P completely blocked EMT (Fig.
6), none of the explants treated with 2.5 μM S1P were able to
produce more than 2 mesenchymal cells, compare Fig. 5B with
C. Most of the cells on the collagen gel surface failed to extend
filapodia and were rounding up (Figs. 5E, F).
Analysis of cell shape revealed an altered cytoskeletal
structure in S1P-treated cells. We observed that cells treated
with S1P formed stress fibers around the inside of the cell, as
highlighted by phalloidin-Alexa Fluor488 staining (Fig. 7).
Upon treatment with 2.5 μM S1P, cells were unable to from
filapodia or lamellipodia and some round up on the surface of
the gel (Fig. 7). Control cultures display cells on the gel surface
with multiple cellular processes that are highly branched,
indicating that these cells are actively migrating on the collagen
matrix (Fig. 7). In contrast to controls, S1P-treated cells on the
surface of the collagen gel present very few cellular extensions,
if any, and those that have small extensions are not branched at
all (Fig. 7). Counterstaining explants with MF20, an antibody to
myosin heavy chain, demonstrate that cardiomyocytes stay
primarily within the explanted tissue and are not the cells
showing altered morphology on the collagen gel surface in
response to S1P treatment (Fig. 7). Elevated S1P appears to
prevent these cells from adopting a fibroblastic phenotype,
characteristic of migratory cells, leaving them with a more
endothelial phenotype.
S1P is required for cell survival in AV canal tissue
Inhibition of S1P production in whole embryo cultures, with
DMS treatment, caused a loss in cellularity in the heart and
cardiac cushions. To assess this observation in more detail, AV
canal cultures were treated with a range of DMS concentrations
(0.5 μM to 2.5 μM). Cultures were then examined for cell death,
cell migration, and mesenchyme formation.
Fig. 4. Decreased S1P production but not elevated S1P levels leads to cell death in AV canal tissue. AV canal explant health was assessed at the end of 48 h in culture
with the LIVE/DEAD Viability/Cytotoxicity kit (Molecular Probes). Cultures treated with either control vehicle (A, D), 2.5 μM S1P (B, E), or 2.5 μM DMS (C, F)
were examined for live (green) or dead (red) cells with confocal scanning laser microscopy. Control and S1P-treated explants both contained a few dead cells around
the periphery of the explants, but the majority of cells within the explant and on the gel surface were alive. In contrast, DMS treatment caused most of the cells with in
the explant to die as indicated by the large number of red cells. Scale bar equals 100 μM.
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cardiomyocyte viability, as 100% of the explants at these
concentrations were beating after 24 and 48 h in culture. A
DMS concentration of 0.5 μM had no effect on either cellular
outgrowth or endothelial to mesenchymal cell transformation in
AV canal cultures (Figs. 6, 8B, G). However, 1.0 μM DMS
inhibited cellular outgrowth by 33% and blocked mesenchymal
formation by 37% (Figs. 6, 8C, G).
The most prominent effects of DMS were observed when
AV canal explants were treated with 2.5 μM DMS. After 24
h of 2.5 μM DMS treatment, 68% of the explants were
beating, and after 48 h, only 27% were still beating compared
with 100% of the controls and 96% of S1P-treated explants
(Table 1). TUNEL analysis performed on 2.5 μM DMS-
treated explants revealed that nearly all of the cells on the
collagen gel surface were positive for apoptosis as well as
many of the cells in the muscle explant (Fig. 9). This
treatment also caused a near complete block in cellular
outgrowth from the explants, and EMT was inhibited 100%
(Figs. 6, 8E, G). The only cells on the surface of the gel
around the muscle explant were dead and rounded up (Figs. 7,
9). Analysis of DMS (2.5 μM)-treated explants with the LIVE/
DEAD kit indicated that most of the cells in and around the
muscle explant were dead (Fig. 4).
The specificity of the DMS treatment was confirmed by the
addition of S1P (0.5 μM)- to DMS (2.5 μM)-treated explants.
S1P increased the outgrowth of cells away from AV canal
explants from 17% to 71% of controls and increased
mesenchyme formation in cultures treated with DMS (Figs.
6, 8F, G). Cardiomyocyte viability was also improved with
S1P treatment. After 48 h, S1P increased the proportion ofbeating explants from 27% to 78% (Table 1). These
experiments show that S1P is required to maintain healthy
AV canal cultures with beating cardiomyocytes and trans-
formed mesenchymal cells.
S1P inhibition of cell migration and EMT is not mediated by
S1P1 or through conversion to ceramide
Treatment with SEW 2871, an S1P1 specific agonist, had
no effect on AV canal cultures. Both cell migration away
from explants and mesenchyme formation were comparable
to vehicle controls (Figs. 6, 10). Examination of cell
morphology, with phalloidin staining, was also comparable
to vehicle treated cultures (data not shown). In addition, SEW
2871 was unable to rescue cellular outgrowth (Fig. 10) or
mesenchymal cell formation (data not shown) in DMS-treated
AV canal cultures. Although S1P1 is expressed in early stage
AV canals, its activation alone failed to recapitulate the
effects of S1P.
Sphingosine-1-phosphate can be converted into ceramide, a
potent promoter of apoptosis, by first being converted to
sphingosine. Sphingosine is then converted into ceramide by
ceramide synthase (Spiegel and Kolesnick, 2002). To test if
the effects of elevated S1P were due to a conversion of S1P
into ceramide, AV canal cultures were treated with fumonisin
B1 (FB1) which blocks ceramide synthase activity (Le Stunff
et al., 2002). Treatment of AV canal explants with FB1 (5 μM
final concentration) alone had no effect on AV canal
outgrowth (Fig. 11) and only a slight inhibition on
mesenchymal cell formation (data not shown). Treatment of
AV canals with FB1 in the presence of 2.5 μM S1P was
Fig. 5. S1P inhibits cellular outgrowth from AV canal cultures. AV canals
isolated from E9.5 hearts were cultured on collagen gels for 2 h and then treated
with vehicle control (4% FAF-BSA, A, B), 0.5 μM S1P, 1.0 μM S1P (C, D), or
2.5 μM S1P (E, F). Following 48 h of total incubation, phase contrast images
were taken at low magnification to show extent of endothelial and mesenchymal
cell outgrowth away from the muscle explant (A, C, E). Increasing
concentrations of S1P caused a decrease in cellular outgrowth (G). High
magnification shows cell morphology (B, D, F), with high levels of S1P
treatment (1.0 and 2.5 μM) causing cells to round up (D, F). The total area of
outgrowth was determined for each explant by outlining the extent of outgrowth
and subtracting from that the area of the explant, demonstrated in panel A. The
average outgrowth for each treatment was calculated and displayed as a percent
of vehicle control (G). N, number of explants measured for each treatment; M,
muscle explant. Scale bar equals 100 μM. Arrow points to mesenchymal cell.
*P ≤ 0.008, **P ≤ 1 × 10−9.
Fig. 6. Altered S1P signaling inhibits endothelial to mesenchymal cell
transformation (EMT) in AV canal cultures. After 48 h of drug treatment, the
amount of EMT in E9.5 AV canal cultures was determined. Using a phase
contrast microscope, live cultures were scored for the presence of transformed
mesenchymal cells that had invaded the collagen gel matrix. Explants were
scored as inhibited if 0–2 mesenchymal cells were found in the gel surrounding
the explant. Results are displayed as the percent of explants with impaired EMT.
Increasing S1P concentrations progressively inhibit mesenchymal cell formation
in the AV canal cultures, and the highest concentration of S1P (2.5 μM)
completely blocks EMT. The highest level of DMS (2.5 μM) also completely
blocks EMT. However, a low amount of S1P (0.5 μM) rescues EMT in DMS
(2.5 μM) treated cultures. In addition, this graph reveals that 2.5 μMSEW 2871,
an S1P1 agonist, has no affect on EMT in these cultures. N equals the number of
explants examined for each drug treatment.
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formation (Fig. 11). These data indicate that S1P signaling
involves direct effects on AV canal development, rather than
through a conversion to ceramide.Discussion
Sphingosine-1-phosphate is a signaling molecule that affects
many different cellular processes, including cell proliferation
and cell migration, in a variety of cardiovascular cell types
including vascular smooth muscle cells, cardiomyocytes, and
endothelial cells (Takuwa, 2002). Much effort has focused on
the role of S1P signaling during the development of the vascular
system and on the function of vascular tissue, but relatively little
is known about S1P signaling during heart development. This
report demonstrates that S1P signaling is important for cardiac
development, and that alterations in S1P level can lead to
cardiac malformations or cell death. This is the first evidence
indicating that S1P signaling in cardiac tissue is important for
heart development.
Local production of S1P by sphingosine kinase 1 and 2
(SK1, SK2) is reported in adult mammalian hearts and in whole
mouse embryos as early as E7.5 (Argraves et al., 2004; Liu et
al., 2000a). Using RT-PCR analysis, we extend this analysis by
documenting SK1 and SK2 expression in cardiac tissue as early
as the linear heart tube stage (E8.5) and continuing through
formation of the four-chamber heart at E12.5, the latest stage
examined (Fig. 1). One method to inactivate S1P signaling is
conversion to sphingosine by S1P phosphatase (Pyne et al.,
2004). Both mouse and human S1P phosphatase 1 (SPP1) have
been characterized and are expressed in adult heart tissue
(Johnson et al., 2003; Mandala et al., 2000). Our findings show
SPP1 expression in the heart as early as E8.5 and throughout the
early stages of cardiac development (E8.5–E12.5; Fig. 1). The
expression data for SK and SPP1 support the idea that S1P
Fig. 7. S1P treatment prevents cell shape changes required for mesenchymal cell formation. AV canal cultures from E9.5 hearts were cultured on collagen gels for
48 h with vehicle control (4% FAF-BSA, A–D), 2.5 μM S1P (E–H), or 2.5 μM DMS (I–L). The actin cytoskeleton of AV canal cells was detected with phalloidin
conjugated to Alexa Fluor488. Phalloidin labels all cells in the AV canal cultures including cells in the explant and cells that have migrated away from the explant
(A, E, I). MF20, a muscle-specific antibody to myosin heavy chain, identified cardiomyocyte cells within the AV canal explants (B, F, J). An overlay of the
phalloidin and myosin staining demonstrates that cardiomyocytes do not migrate away from the explants (C, G, K). A closer examination at higher magnification
reveals the morphology of cells on the collagen gel surrounding the muscle explants (D, H, L). Vehicle-treated cultures have numerous mesenchymal cells, each
with many filapodia, migrating away from the explant (D). In contrast, cells in S1P-treated cultures have few cellular processes, and they retain cell to cell contacts
characteristic of an endothelial phenotype (H). DMS treatment causes cells on the gel surface to round up (L). Scale bar equals 100 μM, except panels D, H, L
where the scale bar is 50 μM.
272 C.C. Wendler, S.A. Rivkees / Developmental Biology 291 (2006) 264–277levels are locally regulated in cardiac tissue during early heart
development.
Two other pieces of data described in this report support the
idea that regulation of S1P, specifically, is critical for cardiac
cushion development. First, fumonisin B1 was not able to rescue
S1P-treated AV canal cultures (Fig. 11), indicating that effects
of increased S1P are not caused by a conversion into ceramide.
Second, DMS-treated cultures were rescued by exogenous S1P,
indicating that DMS-induced cell death was caused by a
reduction in S1P levels (Fig. 8).
Although S1P can act as a 2nd messenger inside the cell, the
majority of S1P influences on cell signaling are attributed to
binding cell surface receptors (Anliker and Chun, 2004; Payne
et al., 2002; Watterson et al., 2003). S1P receptor expression has
recently been reported in the developing murine embryo,
allantois, and yolk sac (Argraves et al., 2004). We observed four
S1P receptors (S1P1–4) expressed in the developing embryofrom E7.5 through E12.5, and the same receptors were detected
in the developing heart from E8.5 to E12.5 (Fig. 1). A new
finding was that S1P4, which is almost exclusively expressed in
the lymphoid tissue (Graler et al., 1998), was detected in
embryonic cardiac tissue (Fig. 1).
Whole embryo cultures revealed a link between S1P
signaling and cardiac cushion formation since both an increase
and a decrease in S1P reduced the number of cells within the AV
canal cushions (Fig. 3). These results begin to indicate that
maintaining the local S1P concentration within a narrow range
is critical for proper cardiac development. Experiments with
isolated AV canals in culture confirm the sensitivity of this
tissue to changes in S1P concentration and suggest that different
mechanisms are responsible for disrupted cushion development
depending on whether S1P levels go up or down. The in vitro
cultures indicate that elevated S1P prevents cell migration (Fig.
5) and that decreased S1P causes cell death (Fig. 9), and that
Fig. 8. Sphingosine kinase activity is required for cellular outgrowth in AV canal
cultures. AV canals isolated from E9.5 hearts were cultured on collagen gels and
treated with vehicle control (0.08% ETOH in 4% FAF-BSA, A), 0.5 μM DMS
(B), 1.0 μM DMS (C, D), 2.5 μM DMS (E), 2.5 μM DMS + 0.5 μM S1P (F).
Following 48 h of incubation, phase contrast images of live cultures were taken
at low magnification (A, B, C, E, F) to show the extent of endothelial and
mesenchymal outgrowth from the muscle explant. DMS treatment of 1.0 and 2.5
μM inhibited outgrowth (C, E), which was rescued with addition of exogenous
S1P (F). High magnification shows rounded cell morphology in 1.0 μM (D) and
2.5 μM (data not shown) DMS-treated cultures. All scale bars are 100 μM. The
average areas of outgrowth from AV canals were calculated for each treatment
group and represented as a percent of vehicle control (G). N, number of explants
measured for each treatment. Scale bar equals 100 μM. *P ≤ 0.01,
**P ≤ 1 × 10−14, ***P ≤ 1 × 10−8.
Fig. 9. Inhibition of S1P production induces cell death in AV canal tissue. E9.5
AV canal cultures were treated with vehicle (A, C, E) or 2.5 μMDMS (B, D, F).
Cultures were fixed after 48 h, and TUNEL analysis was performed. DMS
treatment caused a tremendous amount of cell death in the AV canal cultures
compared to very little cell death in control cultures (C, D). Cultures were then
immunostained with MF20 to identify muscle cells (A, B). TUNEL analysis
revealed that DMS treatment was inducing cell death of cardiomyocyte within
the explant as well as in non-muscle cells present on the collagen gel surface (F).
Arrows indicate non-muscle cells. Scale bar equals 100 μM.
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cushions.
The transformation of endothelial cells into mesenchymal
cells that then invade the cardiac cushions is critical for proper
valve formation (Chin et al., 1992; Thompson and Fitzharris,
1979). Unlike chicken AV canal explants, which have sheets of
endothelial cells spreading out from the muscle explant, mouse
AV canal explants have fewer endothelial cells spread on the gel
surface (Fig. 5). The vast majority of cells that migrate away
from mouse AV canal explants have a cell shape characterized
by many cellular processes (lamellipodia and filapodia)
extending out from the cell body. Control explants have many
of these fibroblastic type cells migrating away form the muscle
explant, some on the surface of the gel and some that invade the
collagen gel (Fig. 7). Like chicken cultures, the cells that invade
the collagen gel are identified as mesenchymal cells (Fig. 5).
Increasing S1P concentrations in AV canal cultures progres-
sively inhibited cellular outgrowth away from the muscle
Fig. 10. S1P1 agonist (SEW 2871) has no effect on AV canals. (A) Phase contrast
image of normal outgrowth from an AV canal culture after 48 h of exposure to
SEW 2871, an S1P1-specific agonist. Quantitation of endothelial cell outgrowth
from SEW 2871-treated AV canal muscle explants (M) demonstrated no
difference from vehicle treated explants (C). Unlike S1P, SEW 2871 is unable to
rescue DMS-induced outgrowth inhibition (B, C). Final concentrations for all
drugs were 2.5 μM. The number of explants (N) measured for each treatment:
vehicle, N = 13; SEW 2871, N = 13; DMS, N = 20; SEW 2871 + DMS, N = 4.
Scale bar equals 100 μM.
Fig. 11. S1P inhibition of outgrowth is not through conversion to ceramide. (A)
Phase contrast image revealing normal cellular outgrowth from an AV canal
explant treated with 5 μM fumonisin B1 (FB1), an inhibitor of ceramide
synthase. FB1 blocks the conversion of sphingosine into ceramide and is unable
to rescue mesenchymal cell outgrowth in S1P-treated explants (B, C). N, number
of explants measured for each treatment. Scale bar equals 100 μM.
*P ≤ 1 × 10−8.
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number of explants with transformed mesenchyme (Figs. 5, 6).
At low levels of S1P concentration (0.5 μM), cellular outgrowth
was 61% of controls, and the amount of EMT was 63% of
controls. At 1.0 μM S1P, cell outgrowth is reduced to 38% of
control, and EMT is like wise reduced to 38% of controls (Figs.
5, 6). Finally, at higher concentrations of S1P (2.5 μM),
outgrowth is only 23% of controls, and EMT has been
completely blocked (Figs. 5, 6). This increasing inhibition in
cell migration is associated with changes in morphology of cells
on the surface of the collagen gels (Fig. 7). S1P treatment
prevents cells from forming migratory cells with many
filapodia. Instead, S1P causes cells on the surface of the gel
to maintain an endothelial phenotype with few cellular
processes and more cell–cell contacts (Fig. 7). These findings
suggest that reduced EMT in S1P-treated cultures is due to an
inhibition of cell migration.
Although in many systems S1P promotes cell migration (Lee
et al., 1999; Wang et al., 1999), there is evidence that S1P can
trigger a rearrangement of the cytoskeleton that leads to an
inhibition of cell migration (Okamoto et al., 2000; Olivera et al.,
2003). Over-expression of SK1 in NIH 3T3 cells induced stress
fibers and inhibited cell migration, and this effect was mediated
by G12/13 and Rho signaling (Olivera et al., 2003). S1P causes
cell rounding in HEK 293 and CHO cells which was mediated
by the S1P2 and S1P4 respectively, and S1P induced peripheralstress fibers similar to those seen in S1P-treated AV canal
cultures (Graler et al., 2003; Van Brocklyn et al., 1999). S1P can
also inhibit cell migration in tumor cells (Lepley et al., 2005).
This effect is mediated through S1P2 and the Rho/Rho kinase
pathway and leads to changes in the actin cytoskeleton (Lepley
et al., 2005).
A cell's migratory response to S1P stimulation is dependent
on which S1P receptor(s) are activated (Takuwa, 2002).
Activation of S1P1 or S1P3 promotes cell migration of
endothelial cells and of CHO cells over-expressing these
receptors (Kon et al., 1999; Lee et al., 1999; Okamoto et al.,
2000). In contrast, the S1P2 receptor blocks cell migration in
several cell types including neutrophils, B16 melanoma cells,
vascular smooth muscle cells, and CHO cells over-expressing
S1P2 (Bornfeldt et al., 1995; Kawa et al., 1997; Okamoto et al.,
2000; Sadahira et al., 1992). Since S1P1 is known to promote
cell migration, it is unlikely that this receptor is mediating the
S1P response seen in cardiac cushions. This idea was
strengthened when no effects on cell migration or transforma-
tion were observed with SEW 2871, an S1P1-specific agonist,
treatment of AV canal cultures (Fig. 10). In addition, SEW 2871
was unable to rescue cell migration, EMT or even cell survival
in DMS-treated cultures (Fig. 10). These data indicate that Gi
protein, the only G protein that S1P1 signals through, is not
involved in the disruption of cardiac cushion development
caused by elevated S1P levels.
S1P2 is a possible candidate as the mediator of S1P signaling
in AV canals, since it inhibits cell migration and causes cell
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S1P treatment in other systems (Osada et al., 2002; Van
Brocklyn et al., 1999). S1P2 can signal through Gi, but it would
likely signal through one or both of the other G proteins (G12/13,
Gq) that it interacts with (Anliker and Chun, 2004), in order to
inhibit cell migration in cushion tissue. Two other S1P receptors
(S1P3 and S1P4) expressed in AV canal tissue cannot be ruled
out as mediators of S1P signaling either because they also signal
through G proteins other than Gi. S1P3 interacts with G12/13 and
Gq and S1P4 signals through G12/13 (Anliker and Chun, 2004;
Graler et al., 2003).
Although we speculate that S1P2 is the mediator of S1P
signaling in cardiac cushions, gene knockout experiments show
that S1P2 is not required for normal development (Kono et al.,
2004). This contradiction may be explained by a redundancy in
function of known cardiac S1P receptors or by as yet
unidentified S1P receptor(s). Alternatively, S1P effects on
cultured AV canals may be caused by the activation of multiple
S1P receptors. S1P acting as a second messenger inside the cell
could be another pathway, since reports demonstrate that S1P
can be transported into the cell through the cystic fibrosis
transmembrane regulator (Boujaoude et al., 2001; Meyer zu
Heringdorf et al., 2001).
Experiments have demonstrated that VEGF signaling is
critical for preventing EMT in areas outside the cardiac
cushion and within the cardiac cushion later in development
to bring cell transformation to an end (Chang et al., 2004;
Dor et al., 2001). A reduction in VEGF also inhibits AV
canal EMT (Enciso et al., 2003). In addition, VEGF
activates sphingosine kinase and increase S1P levels in
human umbilical vein endothelial cells (Shu et al., 2002).
These observations along with the data presented in this
report raise the possibility that S1P mediates the effects of
VEGF on cardiac cushions during heart development.
Another possibility is that factors that are highly angiogenic,
like S1P and VEGF, maintain endothelial cells in a
proliferative state that is resistant to cell transformation
signals. This could also explain why the complete lose of
these factors is also detrimental to endothelial cells and the
formation of mesenchymal cells.
This report provides evidence that elevated S1P is acting to
prevent the formation and migration of mesenchymal cells.
What is not yet clear is whether S1P acts directly on endothelial
cells or indirectly through alterations in cardiomyocyte
signaling. Overall, our findings indicate that careful regulation
of S1P signaling is important for cardiac viability and
morphogenesis. Further analysis of factors that regulate S1P
levels in cardiac tissue will be an important step in describing
the role of S1P during normal heart development.Acknowledgments
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